Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

"At one point, Modifi was on the brink of collapse. But the startup clawed its way back with an infusion of seed money, much of it from charitable organizations including the American Cancer Society’s BrightEdge, The Sontag Foundation and the National Brain Tumor Society. A 2022 study validated the approach, which helped convince Merck of its potential."

Dr. Ranjit Bindra
Co-Founder, Modifi Biosciences

Why the Sontag Innovation Fund?

Sontag Innovation Fund venture philanthropy investments will build on the impact created by the Sontag Foundation, the largest private donor to primary brain cancer research in the United States. We have over two decades of experience working with the best brain cancer scientists in the world. Our experience as brain cancer philanthropists with a venture philanthropy focus, combined with our vast network of scientists, hospitals, universities, and investors bring our portfolio companies a competitive advantage in delivering our mission to accelerate solutions to diagnose, treat, prevent and cure brain cancer.

Investment Strategy

We focus our resources solely on opportunities to advance our charitable mission. While we take chances in pursuit of impact, we also seek overall return of principal so we can recycle capital and maximize our long-term effectiveness. Our investments are typically structured as loans and equity investments, and we work with both for-profit and non-profit entities.

How We Invest

Brand photography for The Sontag Foundation
Areas of Interest

Therapeutics, Diagnostics, Medical Devices & Other Technologies.

Brand photography for The Sontag Foundation
What We Provide

Patient high-risk capital, intellectual property support, management, and SAB support.

Brand photography for The Sontag Foundation
Our Difference

We are a subsidiary of a premier Brain Tumor focused Foundation established in 2002 with vast expertise in brain tumors and venture investments. In addition, we have established a vast network of top-quality researchers and investors that have a passion to make an impact in the lives of brain tumor patients.

Current Portfolio

Exits

Contact Sontag Innovation Fund

For all inquiries please contact:

Scott Davis, Ph.D.
Managing Director